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CLINICAL INVESTIGATION
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Deferoxamine and coated charcoal hemoperfuslon to remove aluminum
In dialysis patients. We studied the in vitro and in vivo characteristics of
aluminum (Al) removal by coated charcoal hemoperfusion (HP) in
combination with intravenous deferoxamine (DFO). DFO enhanced the
clearance of Al by HP in vitro after 180 minutes of perfusion with a
solution containing 403.3 14.0 ng/ml of Al at 150 mI/mm. The Al
clearance was 139 1.0 mllmin with DFO and 49 10.0 mI/mm (P <
0.001) without DFO. Addition of DFO enhanced in vitro Al removal
from 5.5 0.9 mg to 10.0 1.2 mg (P < 0.05). During our in vivo
studies, an HP device was in series in the dialysis circuit after a
Cuprophan hemodialyzer. Eight patients with Al toxicity were studied
on twelve occasions. Patients received DFO (40 mg/kg) 40 hours before
the study. The total Al clearance with the combined hemodialysis (HD)
and HP devices was higher than that obtained by the dialyzer alone at
30 minutes (62 4.9 mI/mm vs. 25 2.5 mI/mm, P < 0.02) and after 180
to 210 minutes (32 3.0 ml/niin vs. 19 2.9 mI/mm, P < 0,02). After
120 minutes the Al clearance by the HP device alone was significantly
lower than the initial Al clearance by HP. Combined HD plus HP
removed 2.9 0.4 mg of Al, whereas the total removal of Al by HD
alone was 1.5 0.3 mg (P < 0.01).
There is a growing awareness of the consequences of alumi-
num (Al) toxicity in hemodialysis (HD) patients. Clinical man-
ifestations of this syndrome include encephalopathy, myop-
athy, fracturing bone disease, and microcytic anemia [1—5].
Although the use of Al-free dialysate initially improved the
symptoms of some patients [6, 7], further work has shown that
deferoxamine (DFO) is effective in improving the outcome of
dialysis patients with clinical manifestations of Al intoxication
[8—17]. Even with DFO, dialysis removal of Al is relatively
inefficient and requires lengthy treatment, which increases the
likelihood of adverse side effects and potential toxicities of
DFO [12, 18—24]. Because of this, we feel that enhanced
removal of the DFO-Al complex would be advantageous in
these patients. Brief reports have indicated the potential use-
fulness of coated charcoal hemoperfusion (HP) in the removal
of DFO-A1 complexes [25, 26]. Small numbers of patients were
studied, and one report [25] contained data that conflicted with
our own experience regarding the efficacy of HD in removing
the DFO-Al complexes [27]. We undertook this study to docu-
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ment more thoroughly the characteristics of Al removal in
Al-toxic HD patients with the combined use of DFO, HD, and
coated charcoal HP.
Methods
In vitro studies
To determine the capacity of the coated charcoal HP device
for removal of Al and DFO-Al complexes, we performed in
vitro studies with three coated charcoal HP devices (Alu-Kart,
National Medical Care, Rockleigh, New Jersey, USA). In the
first part of these in vitro studies, aluminum chloride was added
to deionized water treated with reverse osmosis (Al less than 2
nglml) such that the final Al concentration was 403.3 14.0 ng/
ml (mean SEM). This concentration was chosen in order to
approximate the serum Al levels seen in our in vivo studies. The
Al solution was perfused through each HP device at a flow rate
of 150 mI/mm. There was no recirculation. This flow rate was
chosen to approximate the plasma flow rate used in our in vivo
dialysis procedure. The outflow from the HP device was
sampled at 15, 30, 60, 120, and 180 minutes in order to calculate
Al clearance. To determine Al removal, all of the outflow from
each HP device was collected for Al analysis in an acid-washed
Al-free polypropylene container. Al removal was calculated by
multiplying the outflow volume times the difference in Al
concentration between the inflow and outflow solutions. In part
two of the in vitro studies, the same experiment was repeated
after the addition of DFO to the Al-containing solution in an
amount equimolar to the Al content. This portion of the in vitro
study was carried out for 14 hours, with additional determina-
tions of Al clearance and Al removal performed after 8 and 14
hours.
In vivo studies
Eight HD patients with Al toxicity were studied during 12
treatments. Al toxicity was diagnosed by the presence of (a) or
(b), plus (c) or (d): (a) bone biopsy showing osteomalacia or
low-turnover bone disease with at least 50% of the trabecular
surfaces staining positively for Al [28, 29]; (b) positive DFO
infusion test [30]; (c) neurologic symptoms or electroencepha-
logram showing changes suggestive of Al toxicity [6]; (d)
erythrocyte microcytosis in the absence of iron deficiency [3,
5]. Six patients were studied during the initial month of their
chronic weekly DFO therapy and two patients were studied
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Fig. 1. Extracorporeal circuit used for combined coated charcoal
hemoperfusion and hemodialysis.
after two months of weekly DFO therapy. The patients received
the usual weekly dose of DFO, 40 mg/kg, administered intra-
venously after the completion of a regular HD.
Approximately 40 hours later, at the time of the next dialysis,
Al clearance studies were performed. The combined HD and
HP treatment (HD + HP) used a Cuprophan hollow-fiber
dialyzer (Travenol CF 15.11, Deerfield, Illinois, USA) and a
coated charcoal HP device (Alu-Kart, National Medical Care).
The HP device was prepared for use according to the manufac-
turer's directions. The HP cartridge was placed into the dialysis
circuit after the dialyzer (Fig. 1). This was performed in this
manner to lessen the organic solute load presented to the HP
device. The water used for dialysis was filtered, passed through
a water softener, and treated with reverse osmosis and deioni-
zation. The Al content of the final dialysate mixture was
undetectably low at less than 2 nglml. Dialysate flow rate was
500 mi/mm and a blood flow rate of 200 mllmin was maintained
by a calibrated blood pump. Each patient's hematocrit and
serum total protein concentration were determined prior to the
treatment. The average plasma flow rate (PFR) for all studies
was 139.2 11.8 ml/min (mean SEM, N = 12). The combined
HD + HP treatment was carried out over three to four hours,
depending upon each patient's dialysis prescription. Serum
samples for determining Al levels were drawn from the arterial
limb of the dialysis circuit (Pre-HD, Fig. 1) at the beginning of
the combined procedure, and Al clearances were determined at
30 and/or 60 minutes, 120 minutes (1 specimen lost), and at the
end of the procedure (180 to 210 mm). To determine Al
clearances of the dialyzer (HD), the HP device (HP), and the
combined devices (HD + HP), blood samples were withdrawn
at these sites at the appropriate times: pre-dialyzer (Pre-HD),
post-dialyzer/pre-hemoperfusion (Post-HD/Pre-HP), and post-
hemoperfusion (Post-HP; Fig. 1). The plasma clearance of Al
was calculated for HD, HP, and HD + HP as follows.
(Al -Al )Al clearance (mllmin) = PFR x pre JOS
pre
The rate of Al removal for HD, HP, and HD + HP was
calculated as follows.
Al removal (ng!min) = (Al clearance) x (Alpre)
All used dialysate was saved in containers that had been well
rinsed with Al-free water. Dialysate removal of Al was quanti-
tated by measurement of the volume and the Al concentration
of this used dialysate. Removal by HP and HD + HP was
estimated by measuring the area under the curve for the
relationship of rate of Al removal (ng/min) versus time (mm).
Al determinations
Details of specimen collection and Al analysis have been
reported [28]. All specimens of blood and dialysate were
collected into acid-washed 10-mi Sarstedt polypropylene sy-
ringes. Blood specimens were allowed to clot for 30 minutes,
and the serum was poured into an acid-washed polypropylene
storage tube. Al levels were quantitated by using flameless
electrothermal atomization and atomic absorption spectroscopy
with a L'vov platform with Zeeman background correction [31].
The reproducibility of this procedure is 5%. The normal
range for serum Al levels in our laboratory is 0 to 6 ng/ml [28].
All values are presented as mean SEM, and statistical
comparisons were made with two-tailed Student t-tests.
Results
In vitro studies
The in vitro clearance of inorganic Al by coated charcoal HP
was 147 1.0 mI/mm at the start, 126 9.8 mI/mm at 30
minutes (P < 0.001 vs. start), and decreased further to 49 10.0
ml/min at 180 minutes (P < 0.001 vs. start) (Fig. 2). With the
addition of an equimolar amount of DFO, the in vitro clearance
of Al also declined throughout the procedure from 147 1.8 ml!
mm to 139 0.9 mI/mm at 180 minutes (P < 0.01). Al clearance
was significantly increased by the addition of DFO at all times—
30, 60, 120, and 180 minutes (all P < 0.001). During the 180
minutes of perfusion with inorganic Al alone, 5.5 0.9mg of Al
was removed, compared with 10.0 1.2mg of Al removed after
the addition of DFO (P < 0.05). Perfusion of the HP device with
the solution containing Al and DFO was carried out for 14
hours. After eight hours, the DFO-enhanced Al clearance
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Fig. 2. In vitro clearance of aluminum by coated charcoal hemoper-
fusion with deferoxamine (-•-) [A! (Cl)3 + DFO] and without DFO (-0-)
[Al (Cl)3 alone]. After 30 mm, aluminum clearance was always higher
with addition of DFO (P < 0.001, N = 3, mean SEM).
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hematologic values because of the previously demonstrated
safety of the coated charcoal hemoperfusion device [32, 33].
Discussion
10
0
0 30 60 90 120 150 180 210
Time on combined hemodialysis
+ hemoperfusion, minutes
Fig. 3. Total aluminum clearance by the combined hemodialysis and
hemoperfusion devices (Lx) was always greater than that obtained by
the hemodialyzer (•) alone. (* P < 0.02). Aluminum clearance by the
hemoperfusion device (0) alone declined by 120 mm (P < 0.005).
Aluminum clearance by HD remained constant during the procedure.
Mean SEM.
declined to 18.7 2.3 ml/min and 15.9 1.4mg of Al had been
removed. After 14 hours of Al-DFO perfusion through the HP
device, the Al clearance was 14.1 1.6 mI/mm and Al removal
was 25.9 1.2 mg (Fig. 2).
In vivo studies
Al clearance with the combined HD and HP devices (HD +
HP) was always greater than that obtained by the dialyzer (HD)
alone (P < 0.02, Fig. 3). After 30 minutes, total Al clearance by
HD + HP was 62 4.9 mi/mm, whereas Al clearance obtained
by HP and HD alone was 46 6.7 mllmin and 25 2.5 mI/mm,
respectively (Fig. 3). Although Al clearance by HD did not
significantly change during the procedure, the Al clearance by
HP was significantly decreased at 120 minutes compared with
the values at 30 and 60 minutes (P < 0.005, Fig. 3). By the
termination of the procedure, HP and HD clearances of Al had
declined to 16 2.4 ml/min and 19 2.9 mI/mm, respectively,
whereas the total Al clearance by HD + HP was 32 3.0 ml!
mm.
The rate of Al removal by combined HD + HP was greater
than that obtained by HD alone at 30 and 60 minutes (P < 0.05,
Table 1). After 120 minutes, the rate of Al removal by the
combined HD + HP procedure was higher than that obtained
by HD alone, but it did not reach statistical significance. Serum
Al levels declined during the procedure (Table 1). The total
removal of Al by HD (determined by used dialysate Al content)
was 1.5 0.3 mg. The approximate amount of Al removal by
HP was 1.4 0.2 mg. The combined HD + HP procedure led
to the removal of 2.9 0.4 mg (P <0.01 vs. HD alone).
Adverse reactions
During this study, the only adverse reaction was a slight ether
odor and ether taste noted by two patients in three of the 12
procedures studied. Blood pressure, pulse, and temperature
were monitored before, during, and after the procedure. We did
not monitor blood platelet number or any other biochemical or
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Our study clearly confirms and extends the early results
reported by Chang and Bane [25] and the abstract by Slato-
polsky et al [26]. Chang and Bane [25] studied only six
DFO-treated patients with the combination of HD and coated
—
charcoal HP. The authors did not note if these patients had Al
— toxicity, and they determined only one value for Al clearance
after 15 minutes of the procedure (65.3 11.2 mI/mm). This
—
compared quite favorably to the total Al clearances that we
____________________________________________
noted after 30 minutes of the procedure (62 4.9 mI/mm). Our
data regarding the clearance of Al by HD in DFO-treated
patients differed from the results of Chang and Bane [25], but
they were similar to the results reported by us in a previous
study [27] and by other authors [13, 34—36], which indicated that
the dialyzer clearance of Al after administration of DFO was 20
to 30 mI/mm. This clearance remained fairly constant through-
out the combined HD + HP procedure. The HP clearance of Al
decreased during the procedure, becoming significantly lower
after 120 minutes. This phenomenon was also noted by Slato-
polsky et al [26] and is supported by data offered by the
manufacturer of the HP device, which indicate that the in vitro
clearance of DFO in aqueous solution (10 mg/mI) declines from
160 ml/min to 105 mI/mm after 120 minutes of perfusion with a
flow rate of 200 mllmin [37]. This suggests that there is a rapid
phase of DFO removal in the initial 120 minutes of perfusion,
followed by a longer, slower phase of removal after that time.
Slatopolsky and co-workers [26] noted that the amount of Al
removed by HD was 1.6 0.2 mg/dialysis and that, with the
addition of the HP cartridge, the Al removal was increased to
2.85 0.14 mg. These results are nearly identical to the findings
that we have reported. Thus, the use of this combined proce-
dure leads to a 75 to 90% increase in Al removal compared with
HD alone.
Our in vitro studies indicate that the charcoal HP device is
capable of binding significant amounts of inorganic Al, but this
Al clearance and Al removal is dramatically increased by the
addition of equimolar amounts of DFO. If we extrapolate the
results depicted in Figure 2, the in vitro Al clearance during
perfusion with aluminum chloride alone would approach zero
after approximately 400 minutes. This would allow for a theo-
retical total Al removal of approximately 7.5 1.1 mg. The
amounts of Al removed at 8(15.9 1.4 mg) and 14 hours (25.0
1.2 mg) were greater than the theoretical maximum amount of
Al removed in the absence of DFO. The amount of DFO-Al
removed in vivo is much less than the theoretical maximum
noted in vitro. This is presumably due to in vivo factors such as
the charcoal binding of other substances in blood that compet-
itively inhibit the binding of the DFO-Al complexes and the
binding of Al to serum proteins [27].
DFO is being recognized increasingly as an effective agent for
treatment of Al toxicity in dialysis patients. Although dialysis
encephalopathy may stabilize with the use of Al-free dialysate
[6, 71, the concomitant use of DFO improves the prognosis of
patients with Al-associated dialysis encephalopathy [4, 8, 10].
DFO also leads to improvement in the histologic variables and
musculoskeletal clinical manifestations of Al-related renal os-
teodystrophy [8—10, 12—14, 16, 17]. These results are due to the
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Table 1. Serum aluminum values and aluminum removal during combined hemodialysis and hemoperfusion
Time
mm
No. of
treatments
Serum aluminum values ng/ml Aluminum removal /xg/min
HD HP HD + HPPre-HD Post-HD/Pre-HP Post-HP
Start 12 411 54.0
30 6 300 64.8 242 50.5 148 25.0 7.3 1.6 11.7 2.9 18.9 4,3a
60 8 348 58.9 298 56.3 239 55.8 7.2 1.8 8.5 2.0 15.6 3.0
120 11 294 51.0 246 43.2 213 43.4 6.6 1.8 4.5 0.9 11.2 2.4
180—210 12 253 42.1 218 37.4 197 36.5 5.1 1.2 3.0 0.4 8.0 1.3
Pre-HD, Post-HD/Pre-HP, and Post-HP refer to sites of aluminum determinations in the extracorporeal circuit (Fig. 1). Abbreviations are: HD,
hemodialysis; HP, coated charcoal hemoperfusion; HD + HP, combined hemodialysis and hemoperfusion. Values are mean SEM.
a P < 0.05 vs. HD alone
fact that DFO markedly increases the removal of Al by dialysis
[13—15, 18, 27, 31]. In the normal state, the ultrafilterable
portion of serum Al is approximately 20% of the total serum Al
[18]. After treatment with DFO, there is a marked increase in
the total serum Al level that is primarily due to the formation of
DFO-Al complexes [27] which increases the ultrafilterable
fraction of Al to 50 to 60% of the total serum Al [18, 27, 36].
Dialysate Al removal is enhanced by the increase in concentra-
tion gradient between ultrafilterable plasma Al and the dialysate
Al concentrations [18, 27] in HD [13—15, 18, 27, 31] and chronic
ambulatory peritoneal dialysis [10, 38—40]. Losses of Al in stool
also may be increased by the use of DFO [41].
Although DFO is extremely useful in the treatment of Al
toxicity in dialysis patients, adverse side effects of DFO have
been described. The most commonly noted adverse reaction to
DFO is hypotension due to vasodilation [12, 181. Ocular and
auditory disturbances [19—22], gastrointestinal upset, and neu-
romuscular irritability may also occur [18]. There also have
been reports of increased seizure activity or worsening of
dialysis encephalopathy coincident with the use of DFO [8, 18].
Some authors report concern about infections that might occur
as a result of DFO therapy [23, 24]. In order to minimize the
development of these potential toxicities, increased efficiency
of Al removal and reductions in the dose and duration of DFO
therapy are desirable. Chang and Barre [25] originally noted
that dialyzer membranes made of polyacrilonitrile (PAN) may
permit better Al clearance. One comparative study found no
difference in Al clearances with Cuprophan and PAN mem-
branes [34], while one brief report has reported a good experi-
ence with AN69 membrane [42]. Isolated reports have shown
that DFO therapy combined with hemofiltration may be effica-
cious in the removal of Al [39, 42—44]. Although hemofiltration
may offer theoretical advantages over Cuprophan hemodialysis
for the removal of Al-DFO complexes, there are few clinical
studies available that might enable one to examine this ques-
tion. We have shown that a coated charcoal HP device is
capable of binding large amounts of Al and DFO-Al complexes.
Previous experience with these devices has shown very few
adverse effects [32, 33]. Limited long-term experience is avail-
able with coated charcoal HP devices, with only a few reports
of hypotension, fever, chills, nausea, and headaches [33]. The
use of HP + HD after the administration of DFO increases the
Al clearance and Al removal above that obtained with HD
alone, and is clinically well tolerated within this acute setting.
This therapy should be considered for patients in whom the
rapid removal of Al and/or avoidance of potential DFO-associ-
ated toxicity is desired. The use of this method may signifi-
cantly shorten the duration of DFO treatment necessary to
reverse Al toxicity. The current cost of a coated charcoal HP
device is approximately double the cost of a weekly dose of 3.0
g of DFO. Medical necessity may mandate the use of this
slightly more expensive, combined treatment modality in order
to accelerate the rate of Al removal in selected Al-toxic dialysis
patients.
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